Last reviewed · How we verify
TT-00420 (tinengotinib)
Tinengotinib is a tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases involved in tumor growth and angiogenesis.
Tinengotinib is a tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases involved in tumor growth and angiogenesis. Used for Advanced or metastatic solid tumors (Phase 3 development).
At a glance
| Generic name | TT-00420 (tinengotinib) |
|---|---|
| Sponsor | TransThera Sciences (Nanjing), Inc. |
| Drug class | Multi-targeted tyrosine kinase inhibitor |
| Target | VEGFR, FGFR, and other receptor tyrosine kinases |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TT-00420 (tinengotinib) inhibits several receptor tyrosine kinases including VEGFR, FGFR, and other kinases implicated in oncogenic signaling. By blocking these kinases, the drug suppresses tumor cell proliferation, angiogenesis, and survival pathways. It is being developed as an oral small-molecule therapeutic for solid tumors.
Approved indications
- Advanced or metastatic solid tumors (Phase 3 development)
Common side effects
- Diarrhea
- Hypertension
- Fatigue
- Nausea
- Anorexia
Key clinical trials
- Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment (PHASE2)
- A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer (PHASE1, PHASE2)
- A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. (PHASE2)
- Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations (PHASE3)
- Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor (PHASE2)
- Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer (PHASE1)
- To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TT-00420 (tinengotinib) CI brief — competitive landscape report
- TT-00420 (tinengotinib) updates RSS · CI watch RSS
- TransThera Sciences (Nanjing), Inc. portfolio CI